#1 Clinical Trials Search in Europe

MOLNUPIRAVIR

Molnupiravir is an oral antiviral medication that has been extensively studied for its potential in treating COVID-19 infections. Developed during the global pandemic, this drug works by introducing errors into the viral RNA during replication, preventing the virus from multiplying effectively. This article examines the various clinical trials investigating molnupiravir’s efficacy, safety, and potential applications across different patient populations with COVID-19.

Table of Contents – [What is Molnupiravir?](#what-is-molnupiravir) – [How Does Molnupiravir Work?](#how-does-molnupiravir-work) – [Medical Uses](#medical-uses) – [Dosage and Administration](#dosage-and-administration) – [Efficacy in COVID-19 Treatment](#efficacy-in-covid-19-treatment) – [Possible Side Effects](#possible-side-effects) – [Special Populations](#special-populations) – [Drug Interactions](#drug-interactions) – [Other Potential Uses](#other-potential-uses) – [Limitations and Considerations](#limitations-and-considerations) – [Conclusion](#conclusion) What is Molnupiravir? Molnupiravir is an oral antiviral medication that was developed to treat COVID-19. It is also known by several other names, including MK-4482, EIDD-2801, and is marketed under the brand name Lagevrio[1]. This medication was developed by Merck Sharp & Dohme (MSD) and received emergency use authorization from regulatory authorities in various countries for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease[2]. How Does Molnupiravir Work? Molnupiravir works through a mechanism known as “viral error catastrophe” or “lethal mutagenesis.” When taken orally, molnupiravir is absorbed into the bloodstream and is converted in the body to its active form called N-hydroxycytidine (NHC)[3]. The active form of molnupiravir (NHC) then distributes into cells where it is phosphorylated to form the pharmacologically active NHC-triphosphate (NHC-TP). When the virus attempts to replicate its genetic material, this active compound is incorporated into the viral RNA by the viral RNA polymerase. The incorporation of NHC causes errors in the viral genetic code, resulting in an accumulation of mutations that prevent the virus from reproducing properly[4]. This process essentially forces the virus to mutate itself out of existence, leading to inhibition of viral replication. This mechanism differs from many other antiviral drugs that typically block specific viral enzymes or prevent the virus from entering cells. Medical Uses # COVID-19 Treatment Molnupiravir is primarily indicated for the treatment of mild to moderate COVID-19 in adults who have tested positive for SARS-CoV-2 and who are at high risk for progression to severe COVID-19, including hospitalization or death. It is designed to be used early in the course of infection, ideally within 5 days of symptom onset[5]. High-risk individuals who may benefit from molnupiravir treatment include those who are: – Over 60 years of age – Have underlying health conditions such as: – Cardiovascular disease – Diabetes – Chronic respiratory disease – Obesity – Compromised immune systems – Cancer – Chronic kidney disease[6] Dosage and Administration The standard recommended dosage of molnupiravir for COVID-19 treatment is: – 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days (a total of 10 doses) – Treatment should be initiated as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset[7] The capsules should be swallowed whole and can be taken with or without food. If a dose is missed, it should be taken as soon as possible if it’s within 10 hours of the scheduled time. If more than 10 hours have passed, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended[8]. Efficacy in COVID-19 Treatment Clinical trials have assessed the efficacy of molnupiravir in treating COVID-19. The most notable study was the MOVe-OUT trial, which showed that molnupiravir reduced the risk of hospitalization or death in unvaccinated adults with mild-to-moderate COVID-19 who were at high risk for severe disease. Key findings from clinical trials include: – A reduction of approximately 30% in the risk of hospitalization or death compared to placebo when treatment was initiated within 5 days of symptom onset[9] – Faster time to negative SARS-CoV-2 viral test results compared to placebo – Reduced duration and severity of COVID-19 symptoms[10] It’s important to note that molnupiravir’s effectiveness appears to be lower than some other COVID-19 treatments like nirmatrelvir/ritonavir (Paxlovid), which has shown a reduction of up to 89% in the risk of hospitalization and death[11]. The PLATCOV platform trial found that molnupiravir accelerated viral clearance in patients with early symptomatic COVID-19, though its arm was eventually closed after meeting pre-defined stopping criteria[12]. Possible Side Effects Molnupiravir is generally well-tolerated, but like all medications, it can cause side effects. Clinical trials have identified several potential adverse reactions: Common side effects (affecting up to 1 in 10 people): – Diarrhea – Nausea – Dizziness – Headache[13] Less common side effects: – Allergic reactions – Altered taste – Fatigue – Vomiting[14] Laboratory abnormalities observed in some patients include: – Decreased white blood cell counts – Increased liver enzymes – Altered blood chemistry values[15] Special Populations # Pregnancy and Breastfeeding Molnupiravir is not recommended for use during pregnancy due to potential fetal harm based on animal reproduction studies. There is a pregnancy surveillance program for women who receive molnupiravir during pregnancy[16]. Women of childbearing potential should use effective contraception during treatment and for 4 days after the last dose. Men who are sexually active with women of childbearing potential should use reliable contraception during treatment and for at least 3 months after the final dose[17]. It is not known whether molnupiravir or its metabolites are present in breast milk. The effects on breastfed infants or milk production have not been studied, so caution is advised for nursing mothers. # Renal and Hepatic Impairment Studies have examined the pharmacokinetics of molnupiravir in patients with renal and hepatic impairment: – For patients with severe renal impairment, research suggests that the plasma pharmacokinetics of NHC (the active metabolite) is similar to that observed in patients with normal renal function, indicating that no dosage adjustment is required[8]. – Similarly, for patients with moderate hepatic impairment, studies indicate that no dosage adjustment is necessary as the pharmacokinetics of NHC is not significantly altered[3]. Drug Interactions One of the advantages of molnupiravir is its relatively low potential for drug interactions compared to some other COVID-19 treatments. Molnupiravir is not metabolized by cytochrome P450 enzymes, which are involved in the metabolism of many medications, reducing the likelihood of significant drug-drug interactions[7]. Clinical studies have investigated potential interactions with other medications, including: – The combination of molnupiravir and Paxlovid (nirmatrelvir/ritonavir) – Other antiviral medications These studies generally indicate minimal clinically significant interactions, making molnupiravir suitable for patients on multiple medications[18]. However, as with any medication, patients should inform their healthcare provider about all other medications they are taking. Other Potential Uses # Influenza Treatment Research is exploring molnupiravir’s potential effectiveness against other viral infections, particularly influenza. A Phase 2a clinical trial (MK-4482-017) is evaluating the efficacy and safety of molnupiravir in healthy participants inoculated with experimental influenza virus[17]. The study is testing whether molnupiravir can: – Reduce peak viral load compared to placebo when initiated 12 hours after inoculation – Reduce viral load area under the curve compared to placebo when initiated 2 days after inoculation # Respiratory Syncytial Virus (RSV) Molnupiravir is also being studied for its potential effectiveness against RSV. The AD ASTRA trial is assessing the antiviral effects of various interventions, including molnupiravir, in patients with early symptomatic RSV infection[19]. Additionally, a Phase 2a trial (MK-4482-017) is evaluating molnupiravir’s efficacy and safety in healthy participants inoculated with experimental RSV[15]. # Dengue Fever The ADAPT (Adaptive Dengue Antiviral Platform Trial) is investigating molnupiravir’s potential antiviral effectiveness in early dengue virus infection[20]. This trial aims to determine if molnupiravir can help clear the dengue virus more quickly and reduce the severity of symptoms. Limitations and Considerations While molnupiravir represents an important addition to COVID-19 treatment options, there are several important limitations and considerations: 1. **Timing**: Molnupiravir is most effective when started early in the course of infection, ideally within 5 days of symptom onset. 2. **Resistance concerns**: Due to its mechanism of action (inducing mutations), there are theoretical concerns about the potential for emergence of new viral variants. Ongoing surveillance is important to monitor for this possibility[4]. 3. **Comparative efficacy**: Other treatments like Paxlovid (nirmatrelvir/ritonavir) have shown higher efficacy rates in reducing hospitalization and death in high-risk COVID-19 patients. 4. **Pregnancy restrictions**: The contraindications for use during pregnancy limit its application in this population. 5. **Vaccination importance**: Molnupiravir is not a substitute for vaccination. COVID-19 vaccines remain the most important tool for preventing severe disease. Conclusion Molnupiravir represents an important oral antiviral option for treating COVID-19, particularly for high-risk patients who cannot take other treatments due to contraindications or drug interactions. Its mechanism of action through viral error catastrophe provides a unique approach to fighting viral infections. While it has shown efficacy in reducing hospitalization and death from COVID-19, its effectiveness appears somewhat lower than some alternative treatments. Its favorable drug interaction profile and ease of oral administration make it a valuable option in certain clinical scenarios. Research continues to explore molnupiravir’s potential application against other viral infections, including influenza, RSV, and dengue fever, which may expand its therapeutic utility in the future. As with any medication, patients should discuss the potential benefits and risks with their healthcare provider to determine if molnupiravir is appropriate for their specific situation.
Aspect Details
Mechanism of Action Molnupiravir is a prodrug that converts to N-hydroxycytidine (NHC), which incorporates into viral RNA during replication causing mutations that prevent the virus from reproducing effectively (viral error catastrophe).
Standard Dosage 800 mg (four 200 mg capsules) taken orally twice daily for 5 days, typically started within 5 days of symptom onset.
Primary Clinical Findings Reduces risk of hospitalization and death by approximately 30% in high-risk, non-hospitalized patients with mild to moderate COVID-19.
Patient Population Most beneficial for adults with mild to moderate COVID-19 who are at high risk for progression to severe disease (elderly, immunocompromised, those with underlying conditions).
Safety Profile Generally well-tolerated with mild side effects including diarrhea, nausea, and dizziness. Not recommended during pregnancy due to theoretical risks to fetal development.
Formulations Studied Primarily capsule formulation; some trials have studied tablet formulations and pharmacokinetic properties in different conditions (fasting vs. with food).
Special Populations Studies have examined use in patients with hepatic or renal impairment, with dosing adjustments potentially needed for severe renal impairment.
Comparative Studies Several platform trials have compared molnupiravir to other COVID-19 treatments including nirmatrelvir/ritonavir (Paxlovid), remdesivir, and monoclonal antibodies.
Additional Applications Being studied for potential efficacy against other viral infections including influenza, respiratory syncytial virus (RSV), and dengue fever.
Regulatory Status Received Emergency Use Authorization in several countries including the US and UK for treatment of mild-to-moderate COVID-19 in high-risk adults.

FAQ

  • How does molnupiravir work against COVID-19? Molnupiravir is an oral antiviral that works as a prodrug, meaning it's converted in the body to its active form called N-hydroxycytidine (NHC). Once activated, it gets incorporated into the viral RNA during replication, causing a buildup of errors in the viral genome that prevents the virus from reproducing properly. This process is known as 'viral error catastrophe' and effectively stops the virus from spreading throughout the body.
  • What patient populations might benefit most from molnupiravir? Clinical trials suggest that molnupiravir is most beneficial for adults with mild to moderate COVID-19 who are at high risk for progression to severe disease. This includes older adults, people with underlying health conditions like diabetes or heart disease, and immunocompromised patients who may not respond well to vaccines. The drug is typically recommended to be started within 5 days of symptom onset for maximum effectiveness.
  • What are the common dosages of molnupiravir used in clinical trials? In most clinical trials, molnupiravir has been administered at a dose of 800 mg (four 200 mg capsules) taken orally twice daily for 5 days. Some trials have investigated different dosages, including 200 mg and 400 mg twice daily, but the 800 mg twice daily regimen has been the most commonly studied and eventually became the standard therapeutic dose.
  • What side effects have been reported with molnupiravir in clinical trials? Molnupiravir has generally shown a favorable safety profile in clinical trials. Common side effects include diarrhea, nausea, and dizziness. Unlike some COVID-19 treatments, molnupiravir has not been associated with severe adverse events in most patients. However, the drug is not recommended during pregnancy due to potential risks to fetal development, based on theoretical concerns and animal studies.
  • How effective is molnupiravir compared to other COVID-19 treatments? Clinical trials have shown that molnupiravir can reduce the risk of hospitalization and death by approximately 30% when given early to high-risk patients with COVID-19. This efficacy is lower than some other treatments like Paxlovid (nirmatrelvir/ritonavir), which has shown efficacy rates of around 89%. However, molnupiravir has advantages including fewer drug interactions and may be suitable for patients who cannot take other treatments.

Ongoing Clinical Trials on MOLNUPIRAVIR

  • A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Finland France Germany Italy Poland +2

Glossary

  • Molnupiravir: An oral antiviral medication that works as a prodrug, converting to N-hydroxycytidine (NHC) in the body. It's designed to treat COVID-19 by causing errors in viral replication. Also known by trade names like Lagevrio, and research codes MK-4482 and EIDD-2801.
  • N-hydroxycytidine (NHC): The active metabolite of molnupiravir that gets incorporated into viral RNA during replication, causing mutations that prevent the virus from reproducing effectively.
  • Viral error catastrophe: A mechanism of action where an antiviral drug like molnupiravir causes an accumulation of mutations in the viral genome during replication, eventually preventing the virus from producing viable copies of itself.
  • RNA-dependent RNA polymerase (RdRp): A viral enzyme that molnupiravir targets. This enzyme is responsible for copying the virus's genetic material during replication.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion. PK studies help determine appropriate dosing regimens.
  • Area Under the Curve (AUC): A pharmacokinetic measurement that represents the total drug exposure over time. It's calculated from blood concentration measurements and is important for determining drug efficacy.
  • Maximum Plasma Concentration (Cmax): The peak concentration of a drug in the blood after administration, which helps determine if the dose reaches therapeutic levels.
  • Adverse Event (AE): Any undesirable experience associated with the use of a medical product. Clinical trials carefully monitor and report all AEs to assess drug safety.
  • Standard of Care (SOC): The treatment that is accepted by medical experts as a proper treatment for a certain type of disease. In COVID-19 trials, new treatments are often compared to SOC.
  • Emergency Use Authorization (EUA): A mechanism used by regulatory agencies like the FDA to facilitate availability of medical products during public health emergencies. Molnupiravir received EUA in several countries.
  • Viral Load: The amount of virus in an infected person's body, typically measured from blood or respiratory samples. Reducing viral load is a key goal of antiviral treatments.
  • qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction, a laboratory technique used to detect and measure the amount of viral RNA in samples, commonly used to track viral load in COVID-19 trials.
  • Randomized Controlled Trial (RCT): A study design where participants are randomly assigned to receive either the experimental treatment or a control (placebo or standard treatment), allowing for unbiased comparison.
  • Bioequivalence: The relationship between two pharmaceutical products containing the same active ingredient, showing they have similar bioavailability and produce the same effect.
  • World Health Organization (WHO) Clinical Progression Scale: A standardized scale used to categorize COVID-19 severity and track patient improvement in clinical trials, ranging from uninfected (0) to death (10).

References

  1. https://clinicaltrials.gov/study/NCT06615869
  2. https://clinicaltrials.gov/study/NCT05595824
  3. https://clinicaltrials.gov/study/NCT05386589
  4. https://clinicaltrials.gov/study/NCT06223932
  5. https://clinicaltrials.gov/study/NCT04575597
  6. https://clinicaltrials.gov/study/NCT05459532
  7. https://clinicaltrials.gov/study/NCT05412173
  8. https://clinicaltrials.gov/study/NCT05386758
  9. https://clinicaltrials.eu/trial/a-study-testing-molnupiravir-in-adults-with-covid-19-who-are-not-hospitalized-and-are-at-high-risk-for-serious-illness/
  10. https://clinicaltrials.gov/study/NCT04405570
  11. https://clinicaltrials.gov/study/NCT05894603
  12. https://clinicaltrials.gov/study/NCT05041907
  13. https://clinicaltrials.gov/study/NCT04939428
  14. https://clinicaltrials.gov/study/NCT04575584
  15. https://clinicaltrials.gov/study/NCT05559905
  16. https://clinicaltrials.eu/trial/study-on-the-use-of-casirivimab-cilgavimab-sotrovimab-and-nirmatrelvir-for-patients-with-covid-19-infection/
  17. https://clinicaltrials.gov/study/NCT05818124
  18. https://clinicaltrials.gov/study/NCT04746183
  19. https://clinicaltrials.gov/study/NCT05648448
  20. https://clinicaltrials.gov/study/NCT06551844